Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying
progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with
Stage 4 Chronic Kidney Disease (CKD) and type 2 diabetes receiving standard of care.